Our findings contrast with previous studies in lung cancer patients, where those with low GLI-1 expression showed significantly better progression-free survival with EGFR-TKI erlotinib treatment compared to those with high GLI-1 expression [35]. This evidence concerns the gene GLI1 and lung carcinoma.